Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Ruschitzka

Showing results (31-40 of 522) with videos related to

Pageof 53
Sort By:
Current Hypertension Reports|April 29, 2010
Anti-VEGF therapies and blood pressure: more than meets the eyeFrank Enseleit, Stephan Michels, Frank Ruschitzka
European Heart Journal|October 29, 2015
Peri-infarct pacing to prevent left reverse remodelling: an unvalidated concept?Christophe Leclercq, François Dievart, Frank Ruschitzka
European Journal of Heart Failure|May 3, 2016
HeartFailureNews, new in EJHFMarco Metra, Gerasimos Filippatos, Frank Ruschitzka
Circulation|August 17, 2005
To the heart of the matter: coxibs, smoking, and cardiovascular riskMatthias Hermann, Henry Krum, Frank Ruschitzka
Handbook of Experimental Pharmacology|July 31, 2020
Blood Pressure-Lowering TherapyIsabella Sudano, Elena Osto, Frank Ruschitzka
Current Hypertension Reports|January 16, 2002
Vasopeptidase inhibition: effective blood pressure control for vascular protectionThomas Quaschning, Frank Ruschitzka, Thomas F Lüscher
Expert Opinion on Investigational Drugs|July 12, 2008
Darusentan: a new perspective for treatment of resistant hypertension?Frank Enseleit, Thomas F Lüscher, Frank Ruschitzka
Therapeutic Advances in Cardiovascular Disease|July 28, 2010
Darusentan, a selective endothelin A receptor antagonist, for the oral treatment of resistant hypertensionFrank Enseleit, Thomas F Lüscher, Frank Ruschitzka
Swiss Medical Weekly|April 11, 2013
Destination therapy--time for a paradigm change in heart failure therapyMarkus J Wilhelm, Frank Ruschitzka, Volkmar Falk
European Heart Journal|May 1, 2016
Finerenone in heart failure: walking a fine lineMatthias Naegele, Adrian F Hernandez, Frank Ruschitzka
Pageof 53

Showing results (31-40 of 522) with videos related to

Sort By:
Pageof 53
Current Hypertension Reports|April 29, 2010
Anti-VEGF therapies and blood pressure: more than meets the eyeFrank Enseleit, Stephan Michels, Frank Ruschitzka
European Heart Journal|October 29, 2015
Peri-infarct pacing to prevent left reverse remodelling: an unvalidated concept?Christophe Leclercq, François Dievart, Frank Ruschitzka
European Journal of Heart Failure|May 3, 2016
HeartFailureNews, new in EJHFMarco Metra, Gerasimos Filippatos, Frank Ruschitzka
Circulation|August 17, 2005
To the heart of the matter: coxibs, smoking, and cardiovascular riskMatthias Hermann, Henry Krum, Frank Ruschitzka
Handbook of Experimental Pharmacology|July 31, 2020
Blood Pressure-Lowering TherapyIsabella Sudano, Elena Osto, Frank Ruschitzka
Current Hypertension Reports|January 16, 2002
Vasopeptidase inhibition: effective blood pressure control for vascular protectionThomas Quaschning, Frank Ruschitzka, Thomas F Lüscher
Expert Opinion on Investigational Drugs|July 12, 2008
Darusentan: a new perspective for treatment of resistant hypertension?Frank Enseleit, Thomas F Lüscher, Frank Ruschitzka
Therapeutic Advances in Cardiovascular Disease|July 28, 2010
Darusentan, a selective endothelin A receptor antagonist, for the oral treatment of resistant hypertensionFrank Enseleit, Thomas F Lüscher, Frank Ruschitzka
Swiss Medical Weekly|April 11, 2013
Destination therapy--time for a paradigm change in heart failure therapyMarkus J Wilhelm, Frank Ruschitzka, Volkmar Falk
European Heart Journal|May 1, 2016
Finerenone in heart failure: walking a fine lineMatthias Naegele, Adrian F Hernandez, Frank Ruschitzka
Pageof 53